Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus

Rheumatology

Volumn 48, Issue 2, 2009, Pages 198-199

  Suzuki, K ^a   Nagasawa, H ^a   Kameda, H ^a   Amano, K ^a   Kondo, T ^a   Itoyama, S ^b   Tanaka, Y ^c   Takeuchi, T ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RITUXIMAB;

ADULT; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; LETTER; LUNG EMBOLISM; MENINGITIS; MULTIPLE CYCLE TREATMENT; MYELITIS; PARAPLEGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 58749085559     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken421     Document Type: Letter

References (6)

1. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
2. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
3. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17: 191-7.
4. Koike T, Atsumi T. Antiphospholipid antibodies and cell activation: crucial role of p38MAPK pathway. Lupus 2005;24:799-801.
5. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999;94:2217-24.
6. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.